A total of 167 drug samples flagged as ‘not of standard quality’ in December 2025: Health Ministry

The list of NSQ and spurious drugs is put up on the CDSCO portal on a monthly basis as part of routine regulatory surveillance activity

“As many as 167 drug samples were flagged as “not of standard quality” (NSQ) across the country in December 2025,” the Union Health Ministry has said.

In a monthly drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), Central drug laboratories found 74 samples manufactured by various firms to be NSQ, while State drug testing laboratories identified 93 samples that failed to meet prescribed quality standards.

The list of NSQ and spurious drugs is put up on the CDSCO portal on a monthly basis as part of routine regulatory surveillance activity.

“For December 2025, Central drugs laboratories have identified 74 drug samples to be not of standard quality and State drugs testing laboratories have identified 93 drug samples as NSQ,” the statement said.

Identification of drug samples as NSQ is done based on failure of the drug sample in one or more specified quality parameters. “The failure is specific to the drug products of the batch tested by the government laboratory, and it does not warrant any concerns on the other drug products available in the market,” it said.

Meanwhile, four drug samples from North Zone (Ghaziabad) and one each from FDA Ahmedabad, Bihar and Maharashtra were identified as spurious in December. These were manufactured by unauthorised entities using brand names owned by other companies.

“The matter is under investigation, and action will be taken as per the law,” the statement said.

“This action of identifying NSQ and spurious medicines is taken regularly in collaboration with State regulators to ensure that these drugs are identified and removed from the market,” the Ministry said.

Related Posts

PGIMS recalls drug amid probe into deaths

The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

NPPA list brings little relief: No price cut for 25% cancer drugs

Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

For Aakash Healthcare, Community People are Apples of its Eyes

For Aakash Healthcare, Community People are Apples of its Eyes

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Yashoda Medicity: Baby takes a Giant Step in just One Year

Yashoda Medicity: Baby takes a Giant Step in just One Year